CN100549011C - 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶 - Google Patents

用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶 Download PDF

Info

Publication number
CN100549011C
CN100549011C CNB038250470A CN03825047A CN100549011C CN 100549011 C CN100549011 C CN 100549011C CN B038250470 A CNB038250470 A CN B038250470A CN 03825047 A CN03825047 A CN 03825047A CN 100549011 C CN100549011 C CN 100549011C
Authority
CN
China
Prior art keywords
alkyl
compound
aryl
unsubstituted
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB038250470A
Other languages
English (en)
Chinese (zh)
Other versions
CN1703414A (zh
Inventor
M·P·德怀尔
T·J·古兹
K·帕鲁奇
R·J·多尔
K·M·基尔蒂卡
V·M·吉里亚瓦拉布汉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp & Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1703414A publication Critical patent/CN1703414A/zh
Application granted granted Critical
Publication of CN100549011C publication Critical patent/CN100549011C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038250470A 2002-09-19 2003-09-17 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶 Expired - Fee Related CN100549011C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41206302P 2002-09-19 2002-09-19
US60/412,063 2002-09-19

Publications (2)

Publication Number Publication Date
CN1703414A CN1703414A (zh) 2005-11-30
CN100549011C true CN100549011C (zh) 2009-10-14

Family

ID=32030794

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038250470A Expired - Fee Related CN100549011C (zh) 2002-09-19 2003-09-17 用作细胞周期蛋白依赖性激酶抑制剂的新颖咪唑并吡啶

Country Status (18)

Country Link
US (2) US6992080B2 (cg-RX-API-DMAC7.html)
EP (1) EP1539756B1 (cg-RX-API-DMAC7.html)
JP (1) JP4845379B2 (cg-RX-API-DMAC7.html)
KR (1) KR20050052500A (cg-RX-API-DMAC7.html)
CN (1) CN100549011C (cg-RX-API-DMAC7.html)
AR (1) AR041291A1 (cg-RX-API-DMAC7.html)
AT (1) ATE378336T1 (cg-RX-API-DMAC7.html)
AU (1) AU2003295332B2 (cg-RX-API-DMAC7.html)
CA (1) CA2499639C (cg-RX-API-DMAC7.html)
DE (1) DE60317529T2 (cg-RX-API-DMAC7.html)
ES (1) ES2293068T3 (cg-RX-API-DMAC7.html)
IL (1) IL167433A (cg-RX-API-DMAC7.html)
MX (1) MXPA05003058A (cg-RX-API-DMAC7.html)
MY (1) MY133311A (cg-RX-API-DMAC7.html)
NZ (1) NZ538566A (cg-RX-API-DMAC7.html)
TW (1) TWI351405B (cg-RX-API-DMAC7.html)
WO (1) WO2004026867A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200502278B (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1386922B1 (en) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereof, analogues and uses thereof
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
GB9819530D0 (en) 1998-09-09 1998-10-28 Smithkline Beecham Plc Novel compositions and use
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
EP2256106B1 (en) 2003-07-22 2015-05-06 Astex Therapeutics Limited 3,4-disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
GB0418328D0 (en) * 2004-08-17 2004-09-22 Imp College Innovations Ltd Cancer methods and medicaments
WO2006077425A1 (en) * 2005-01-21 2006-07-27 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors and further antitumor agents
EP1845973B1 (en) * 2005-01-21 2015-08-12 Astex Therapeutics Limited Pharmaceutical compounds
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
EP1845974A1 (en) * 2005-01-21 2007-10-24 Astex Therapeutics Limited Pharmaceutical compounds
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
JP2008536817A (ja) * 2005-03-24 2008-09-11 グラクソ グループ リミテッド 胃腸疾患の処置用医薬として有用なイミダゾ(1,2−a)ピリジン誘導体
CA2621983A1 (en) * 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
JP2009528280A (ja) 2006-02-16 2009-08-06 シェーリング コーポレイション Erkインヒビターとしてのピロリジン誘導体
US20090142337A1 (en) * 2006-05-08 2009-06-04 Astex Therapeutics Limited Pharmaceutical Combinations of Diazole Derivatives for Cancer Treatment
FR2906250B1 (fr) * 2006-09-22 2008-10-31 Sanofi Aventis Sa Derives de 2-aryl-6phenyl-imidazo(1,2-a) pyridines, leur preparation et leur application en therapeutique
EP2099798A1 (en) * 2006-12-01 2009-09-16 Galapagos N.V. Imidazolopyridine compounds useful for the treatment of degenerative and inflammatory diseases
JP5442449B2 (ja) 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
CN101679408B (zh) 2006-12-22 2016-04-27 Astex治疗学有限公司 作为fgfr抑制剂的双环杂环化合物
TWI428132B (zh) 2007-07-02 2014-03-01 Lilly Co Eli 癌症化療效果之強化
GB0720041D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New Compounds
GB0720038D0 (en) 2007-10-12 2007-11-21 Astex Therapeutics Ltd New compounds
EP2229390B1 (en) * 2007-12-14 2014-04-09 F. Hoffmann-La Roche AG Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives
US8426441B2 (en) 2007-12-14 2013-04-23 Roche Palo Alto Llc Inhibitors of bruton's tyrosine kinase
TWI441820B (zh) * 2007-12-19 2014-06-21 Genentech Inc 5-苯胺咪唑并吡啶及使用方法
JP5496915B2 (ja) 2008-02-13 2014-05-21 シージーアイ ファーマシューティカルズ,インコーポレーテッド 6−アリール−イミダゾ[1,2−a]ピラジン誘導体、その製造方法、及びその使用方法
CN102015693B (zh) 2008-02-21 2014-10-29 默沙东公司 作为erk抑制剂的化合物
GB0810902D0 (en) 2008-06-13 2008-07-23 Astex Therapeutics Ltd New compounds
EP2300466B1 (en) 2008-06-20 2014-08-06 Bristol-Myers Squibb Company Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors
CA2726460C (en) * 2008-07-15 2017-02-21 F. Hoffmann-La Roche Ag Novel phenyl-imidazopyridines and pyridazines
EP2348018A4 (en) * 2008-09-25 2012-04-25 Kyorin Seiyaku Kk HETEROCYCLIC BIARYL DERIVATIVE AND PDE INHIBITOR CONTAINING ACTIVE SUBSTANCE
PE20120121A1 (es) 2008-12-08 2012-02-20 Gilead Connecticut Inc Derivados de imidazopirazina como inhibidores de syk
EA020461B1 (ru) 2008-12-08 2014-11-28 Джилид Коннектикут, Инк. ИМИДАЗОПИРАЗИНОВЫЕ ИНГИБИТОРЫ Syk
GB0906472D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
GB0906470D0 (en) 2009-04-15 2009-05-20 Astex Therapeutics Ltd New compounds
PH12012500778A1 (en) 2009-10-30 2012-11-26 Janssen Pharmaceutica Nv IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
JP5938352B2 (ja) 2010-03-11 2016-06-22 ギリアード コネチカット, インコーポレイテッド イミダゾピリジンsyk阻害剤
US20140255392A1 (en) * 2011-04-06 2014-09-11 Bayer Intellectual Property Gmbh Substituted imidazopyridines and intermediates thereof
JP6115962B2 (ja) 2011-06-27 2017-04-19 ヤンセン ファーマシューティカ エヌ.ベー. 1−アリール−4−メチル−[1,2,4]トリアゾロ[4,3−a]キノキサリン誘導体
US8883819B2 (en) 2011-09-01 2014-11-11 Irm Llc Bicyclic heterocycle derivatives for the treatment of pulmonary arterial hypertension
WO2014001314A1 (en) 2012-06-26 2014-01-03 Janssen Pharmaceutica Nv Combinations comprising pde 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and pde 10 inhibitors for use in the treatment of neurological or metabolic disorders
AU2013289284B2 (en) 2012-07-09 2017-03-30 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
PL3027171T3 (pl) 2013-07-30 2020-08-24 Gilead Connecticut, Inc. Formulacja inhibitorów syk
EA029281B1 (ru) 2013-07-30 2018-03-30 Джилид Коннектикут, Инк. Полиморф ингибиторов syk
AU2014360537B2 (en) 2013-12-04 2017-09-07 Gilead Sciences, Inc. Methods for treating cancers
US9290505B2 (en) 2013-12-23 2016-03-22 Gilead Sciences, Inc. Substituted imidazo[1,2-a]pyrazines as Syk inhibitors
TWI662037B (zh) 2013-12-23 2019-06-11 美商基利科學股份有限公司 脾酪胺酸激酶抑制劑
CN106687139A (zh) 2014-07-14 2017-05-17 吉利德科学公司 用于治疗癌症的组合
CN108700594B (zh) 2015-11-18 2021-06-29 建新公司 多囊性肾病的生物标志物及其用途
US10196396B2 (en) 2016-01-14 2019-02-05 Handok Inc. Compounds antagonizing A3 adenosine receptor, method for preparing them, and medical-use thereof
CN110198942B (zh) 2017-01-24 2022-04-15 住友化学株式会社 稠合杂环化合物及含有其的组合物
US10457683B2 (en) * 2017-04-12 2019-10-29 Magenta Therapeutics Inc. Aryl hydrocarbon receptor antagonists and uses thereof
MX2019012431A (es) 2017-04-21 2020-08-03 Ikena Oncology Inc Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos.
KR20220070056A (ko) 2017-08-25 2022-05-27 길리애드 사이언시즈, 인코포레이티드 Syk 억제제의 다형체
AU2020225455A1 (en) 2019-02-22 2021-09-09 Kronos Bio, Inc. Solid forms of condensed pyrazines as Syk inhibitors
AU2020394424A1 (en) 2019-11-26 2022-06-16 Ikena Oncology, Inc. Polymorphic carbazole derivatives and uses thereof
CN120019056A (zh) * 2022-09-28 2025-05-16 原真股份有限公司 新型cdk9抑制剂
CN121866256A (zh) * 2023-09-15 2026-04-14 株式会社汇恩斯 用于预防、减轻或治疗胃肠炎性疾病或胃酸相关疾病的新的基于咪唑并吡啶的化合物和包含其作为活性成分的组合物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5574042A (en) * 1992-11-02 1996-11-12 Fujisawa Pharmaceutical Co., Ltd Imidazo [1,2-a] pyridines and their pharmaceutical use
RU2121997C1 (ru) * 1993-09-10 1998-11-20 Эйсай Ко., ЛТД Производные 7-амино-1н-индола
AU5348396A (en) 1995-05-01 1996-11-21 Fujisawa Pharmaceutical Co., Ltd. Imidazo 1,2-a pyridine and imidazo 1,2-a pyridezine derivati ves and their use as bone resorption inhibitors
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
SE9802794D0 (sv) * 1998-08-21 1998-08-21 Astra Ab New compounds
JP4007743B2 (ja) * 1999-02-26 2007-11-14 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害剤
DE60141889D1 (de) * 2000-02-03 2010-06-02 Eisai R&D Man Co Ltd Inhibitoren der integrinexpression
SE0003186D0 (sv) 2000-09-07 2000-09-07 Astrazeneca Ab New process
CZ20032398A3 (cs) * 2001-03-08 2004-02-18 Astrazeneca Ab Nové použití derivátů 6-karboxamidoimidazo [1,2-a] pyridinu

Also Published As

Publication number Publication date
CA2499639C (en) 2011-11-08
HK1071757A1 (en) 2005-07-29
WO2004026867A2 (en) 2004-04-01
AU2003295332A1 (en) 2004-04-08
AU2003295332B2 (en) 2007-01-18
TW200407322A (en) 2004-05-16
MY133311A (en) 2007-11-30
AR041291A1 (es) 2005-05-11
JP4845379B2 (ja) 2011-12-28
WO2004026867A3 (en) 2004-08-05
DE60317529D1 (de) 2007-12-27
IL167433A (en) 2011-03-31
JP2006507254A (ja) 2006-03-02
KR20050052500A (ko) 2005-06-02
US7452902B2 (en) 2008-11-18
ZA200502278B (en) 2006-05-31
US20060030555A1 (en) 2006-02-09
TWI351405B (en) 2011-11-01
ES2293068T3 (es) 2008-03-16
US6992080B2 (en) 2006-01-31
EP1539756A2 (en) 2005-06-15
CA2499639A1 (en) 2004-04-01
US20040097517A1 (en) 2004-05-20
DE60317529T2 (de) 2008-09-25
MXPA05003058A (es) 2005-05-27
CN1703414A (zh) 2005-11-30
ATE378336T1 (de) 2007-11-15
EP1539756B1 (en) 2007-11-14
NZ538566A (en) 2008-02-29

Similar Documents

Publication Publication Date Title
JP4845379B2 (ja) サイクリン依存性キナーゼインヒビターとしてのイミダゾピリジン
JP4799864B2 (ja) サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
CN1701073B (zh) 作为细胞周期蛋白依赖激酶抑制剂的吡唑并[1,5-a]嘧啶
JP5109109B2 (ja) サイクリン依存性キナーゼ阻害剤としての新規イミダゾピラジン
JP4571969B2 (ja) キナーゼインヒビターとしてのピラゾロトリアジン
JP2006503838A (ja) サイクリン依存性キナーゼインヒビターとしての新規イミダゾピラジン
JP2006502184A5 (cg-RX-API-DMAC7.html)
JP2010168406A (ja) サイクリン依存性キナーゼインヒビターとしてのピラゾロピリミジン
CN101541804A (zh) 作为细胞周期素依赖性激酶抑制剂的吡唑并嘧啶
JP2009511477A (ja) サイクリン依存性キナーゼインヒビターとしての、新規なピラゾロピリミジン
US7700773B2 (en) 4-cyano, 4-amino, and 4-aminomethyl derivatives of pyrazolo[1,5-a]pyridines, pyrazolo[1,5-c]pyrimidines and 2H-indazole compounds and 5-cyano, 5-amino, and 5-aminomethyl derivatives of imidazo[1,2-a]pyridines, and imidazo[1,5-a]pyrazines as cyclin dependent kinase inhibitors
CN100475812C (zh) 作为细胞周期蛋白依赖性激酶抑制剂的吡唑并吡啶

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20091014

Termination date: 20120917